Annals of Pediatric Endocrinology & Metabolism


Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches: Fatma Majdoub, Hanene Lassoued Ferjani, Dorra Ben Nessib, Dhia Kaffel, Kaouther Maatallah, Wafa Hamdi; Ann Pediatr Endocrinol Metab. 2023;28(2):98-106. Published online June 30, 2023; DOI: https://doi.org/10.6065/apem.2346058.029
Web of Science 2 Crossref 3; Full text PubReader ePub PDF


Genotype-phenotype correlations and long-term efficacy of pamidronate therapy in patients with osteogenesis imperfecta: Yunha Choi, Soojin Hwang, Gu-Hwan Kim, Beom Hee Lee, Han-Wook Yoo, Jin-Ho Choi; Ann Pediatr Endocrinol Metab. 2022;27(1):22-29. Published online January 25, 2022; DOI: https://doi.org/10.6065/apem.2142144.072
Web of Science 2 Crossref 2; Full text PubReader ePub PDF Supplementary Material


Successful Pamidronate Treatment of Osteogenesis Imperfecta Type III Infant with Multiple Fractures.: Ju Hee Yoon, Jong Uk Baek, Eun Jung Shim, Il Tae Hwang; Ann Pediatr Endocrinol Metab. 2012;17(3):194-197.; DOI: https://doi.org/10.6065/apem.2012.17.3.194
Crossref 1; PDF

Search